Biotech · Public company · Pasadena, CA, US
Xencor Inc
Ticker XNCR · SEC CIK 0001326732
Track this companyFree. Adds Xencor Inc to your Dealase workspace and tells you when its record changes.
Clinical trials255 recruiting or active
Pipeline programs33From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline33
- LenalidomidePhase 2 · Diffuse Large-cell B-cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- Pembrolizumab + Carboplatin + PemetrexedPhase 2 · Nonsquamous Non-small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- PlamotamabPhase 2 · Diffuse Large-cell B-cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- TafasitamabPhase 2 · Diffuse Large-cell B-cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- vudalimabPhase 2 · Ovarian CancerClinicalTrials.gov · fetched Nov 12, 2026
- vudalimab + cabazitaxel or docetaxelPhase 2 · Metastatic Castration-Resistant Prostate CancerClinicalTrials.gov · fetched Nov 12, 2026
- vudalimab + carboplatin + cabazitaxelPhase 2 · Metastatic Castration-Resistant Prostate CancerClinicalTrials.gov · fetched Nov 12, 2026
- Vudalimab + Carboplatin + PemetrexedPhase 2 · Nonsquamous Non-small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- vudalimab + docetaxelPhase 2 · Metastatic Castration-Resistant Prostate CancerClinicalTrials.gov · fetched Nov 12, 2026
- vudalimab + olaparibPhase 2 · Metastatic Castration-Resistant Prostate CancerClinicalTrials.gov · fetched Nov 12, 2026
- vudalimab monotherapyPhase 2 · Metastatic Castration-Resistant Prostate CancerClinicalTrials.gov · fetched Nov 12, 2026
- XmAb18087Phase 2 · Merkel Cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- XmAb18087 ± PembrolizumabPhase 2 · Merkel Cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- XmAb5871Phase 2 · Systemic Lupus ErythematosusClinicalTrials.gov · fetched Nov 12, 2026
- XmAb942Phase 2 · Ulcerative Colitis (UC)ClinicalTrials.gov · fetched Nov 12, 2026
- AMG 424Phase 1 · Relapsed/ Refractory Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
- Keytruda® (pembrolizumab)Phase 1 · Head and Neck Squamous Cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- Keytruda® (pembrolizumab)Phase 1 · Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- Pembrolizumab (Keytruda®)Phase 1 · MelanomaClinicalTrials.gov · fetched Nov 12, 2026
- XmAb®22841Phase 1 · MelanomaClinicalTrials.gov · fetched Nov 12, 2026
- XmAb®23104Phase 1 · Melanoma (Excluding Uveal Melanoma)ClinicalTrials.gov · fetched Nov 12, 2026
- XmAb®808Phase 1 · Head and Neck Squamous Cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- XmAb13676Phase 1 · B-cell Non-Hodgkins LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- XmAb14045Phase 1 · Acute Myelogenous LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- XmAb18087Phase 1 · Neuroendocrine TumorClinicalTrials.gov · fetched Nov 12, 2026
- XmAb20717Phase 1 · MelanomaClinicalTrials.gov · fetched Nov 12, 2026
- XmAb27564Phase 1 · Safety in Healthy VolunteersClinicalTrials.gov · fetched Nov 12, 2026
- XmAb27564Phase 1 · PsoriasisClinicalTrials.gov · fetched Nov 12, 2026
- XmAb541Phase 1 · Ovarian CancerClinicalTrials.gov · fetched Nov 12, 2026
- XmAb662Phase 1 · Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- XmAb808Phase 1 · Ovarian CancerClinicalTrials.gov · fetched Nov 12, 2026
- XmAb819Phase 1 · Clear Cell Renal Cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- Yervoy® (ipilimumab)Phase 1 · Melanoma (Excluding Uveal Melanoma)ClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials25
- Phase 1, Safety and Tolerability Study of XmAb541 and XmAb808 in Advanced Solid TumorsPHASE1 · RECRUITING · started Jun 30, 2026ClinicalTrials.gov NCT07593092 · fetched Nov 12, 2026
- Study of XmAb942 in Healthy Participants and Participants With Ulcerative ColitisPHASE1_PHASE2 · RECRUITING · started Oct 10, 2024ClinicalTrials.gov NCT06619990 · fetched Nov 12, 2026
- Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid TumorsPHASE1 · RECRUITING · started Apr 4, 2024ClinicalTrials.gov NCT06276491 · fetched Nov 12, 2026
- Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLCPHASE1_PHASE2 · TERMINATED · started Dec 27, 2023ClinicalTrials.gov NCT06173505 · fetched Nov 12, 2026
- Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate CancerPHASE1 · TERMINATED · started Aug 3, 2023ClinicalTrials.gov NCT05733351 · fetched Nov 12, 2026
- A Study of XmAb®662 as Monotherapy or in Combination With Pembrolizumab in Advanced Solid TumorsPHASE1 · TERMINATED · started Jul 28, 2023ClinicalTrials.gov NCT05996445 · fetched Nov 12, 2026
- A Study of XmAb23104 in People With SarcomaPHASE2 · TERMINATED · started Apr 6, 2023ClinicalTrials.gov NCT05879185 · fetched Nov 12, 2026
- XmAb23104 (PD1 X ICOS) and XmAb22841 (CTLA-4 X LAG3) in Treating Melanoma Prior Immune Checkpoint Inhibitor TherapyPHASE1 · TERMINATED · started Feb 28, 2023ClinicalTrials.gov NCT05695898 · fetched Nov 12, 2026
- Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid TumorsPHASE1 · COMPLETED · started Dec 14, 2022ClinicalTrials.gov NCT05585034 · fetched Nov 12, 2026
- Multiple Ascending-Dose Study of XmAb®27564 in Patients With Psoriasis or Atopic DermatitisPHASE1 · TERMINATED · started Oct 10, 2022ClinicalTrials.gov NCT06005792 · fetched Nov 12, 2026
- A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary MalignanciesPHASE2 · ACTIVE_NOT_RECRUITING · started Jul 21, 2022ClinicalTrials.gov NCT05032040 · fetched Nov 12, 2026
- Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell CarcinomaPHASE1 · RECRUITING · started Jun 13, 2022ClinicalTrials.gov NCT05433142 · fetched Nov 12, 2026
- Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (R/R) Diffuse Large-cell B-cell Lymphoma (DLBCL)PHASE2 · TERMINATED · started Apr 15, 2022ClinicalTrials.gov NCT05328102 · fetched Nov 12, 2026
- XmAb20717 in Advanced Biliary Tract CancersPHASE2 · COMPLETED · started Apr 11, 2022ClinicalTrials.gov NCT05297903 · fetched Nov 12, 2026
- XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate CancerPHASE2 · COMPLETED · started Oct 22, 2021ClinicalTrials.gov NCT05005728 · fetched Nov 12, 2026
- Safety and Efficacy of XmAb18087 ± Pembrolizumab in Advanced Merkel Cell Carcinoma or Extensive-stage Small Cell Lung CancerPHASE1_PHASE2 · TERMINATED · started May 10, 2021ClinicalTrials.gov NCT04590781 · fetched Nov 12, 2026
- Safety, Tolerability and PK of a Single Subcutaneous Injection of XmAb27564 in Healthy VolunteersPHASE1 · COMPLETED · started Apr 19, 2021ClinicalTrials.gov NCT04857866 · fetched Nov 12, 2026
- A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid TumorsPHASE1 · COMPLETED · started May 29, 2019ClinicalTrials.gov NCT03849469 · fetched Nov 12, 2026
- A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)PHASE1 · COMPLETED · started May 1, 2019ClinicalTrials.gov NCT03752398 · fetched Nov 12, 2026
- Study Evaluating AMG 424 in Subjects With Multiple MyelomaPHASE1 · TERMINATED · started Jul 31, 2018ClinicalTrials.gov NCT03445663 · fetched Nov 12, 2026
- A Study of XmAb®20717 in Subjects With Selected Advanced Solid TumorsPHASE1 · COMPLETED · started Jul 10, 2018ClinicalTrials.gov NCT03517488 · fetched Nov 12, 2026
- A Study of XmAb®18087 in Subjects With NET and GISTPHASE1 · COMPLETED · started Jan 22, 2018ClinicalTrials.gov NCT03411915 · fetched Nov 12, 2026
- Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic MalignanciesPHASE1 · COMPLETED · started Oct 1, 2016ClinicalTrials.gov NCT02924402 · fetched Nov 12, 2026
- PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic MalignanciesPHASE1 · COMPLETED · started Aug 1, 2016ClinicalTrials.gov NCT02730312 · fetched Nov 12, 2026
- A Study of the Effect of XmAb®5871 in Patients With Systemic Lupus ErythematosusPHASE2 · COMPLETED · started Feb 16, 2016ClinicalTrials.gov NCT02725515 · fetched Nov 12, 2026
SEC filings12
- 10-Q · 10-QSEC EDGAR · filed Nov 4, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Nov 4, 2026 · fetched Nov 12, 2026
- 8-K · CURRENT REPORTSEC EDGAR · filed Oct 26, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Aug 5, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 5, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jul 29, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 18, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed May 6, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 6, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 5, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Apr 27, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Mar 9, 2026 · fetched Nov 12, 2026